Nordic Life Science 1
A C Q UI S I T ION AMGEN HAS AGREED TO BUY THE BI
OPHARMACEUTICAL COMPANY NUEVOLUTION TO BOOST ITS POSITION IN DRUG DISCOVERY. HE OFFER FROM Amgen follows a collaboration between Nuevolution and Amgen which started in October 2016. Amgen had exercised opt-in rights for two cancer treatment approaches that have emerged from the alliance. “Going forward, and provided that the transaction goes through, Amgen wishes to keep Nuevolution in its strongest setup, and Nuevolution will play a key role together with our many coming colleagues at Amgen. We will join efforts in discovery of small molecule-based (tablet) medicines, where Nuevolution will continue its operations from Copenhagen, where about 50 people from about 10 countries are working today,” says Alex Haahr Gouliaev, CEO of Nuevolution. “Personally, I am excited about this opportunity, and I think that we should collectively be proud about this. It is the result of many people’s effort and professional and private investors’ support over many years.” Alex Haahr Gouliaev, CEO, Nuevolution PHOTO THOMAS RØNN